Pentasol

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Pentasol

What is Pentasol? (Clobetasol Propionate)

Property Description
Active ingredient Clobetasol Propionate
Form Topical Cream, Ointment, Solution, etc.
Pharmacological class Corticosteroid (Topical Adrenocorticoid)
Common use Reduction of severe inflammation and itching
Origin Synthetic, Propionate Ester Derivative

What Type of Medicine is Pentasol? (Clobetasol Propionate)

Pentasol is a prescription-only medication that belongs to the pharmacological class of topical adrenocorticoids, widely referred to as corticosteroids. Its active ingredient is Clobetasol Propionate, a synthetic compound derived from prednisolone. This potent molecule is classified under the WHO ATC code D07AD01, placing it within the highest potency group for dermatological use. This super-high potency classification is clinically recognized for its profound action, indicating that it is specifically reserved for managing highly resistant or severe inflammatory skin conditions.


Composition and Available Forms

The medicine is a single active ingredient product that is comprised solely of Clobetasol Propionate combined with a necessary carrier base for topical use. As an external application, it is available across multiple common pharmaceutical preparations to suit various skin areas and conditions. These widely utilized dosage forms include cream, ointment, solution, foam, gel, lotion, spray, and shampoo. The chemical structure of Clobetasol Propionate is fluorinated in nature. The availability of multiple preparations allows for targeted application to specific surfaces, such as the use of the solution form for the scalp.


General Purpose and Benefit

The general purpose of this potent medicine is to provide strong symptomatic relief by intensely suppressing severe skin inflammation. The fundamental anti-inflammatory and antipruritic capabilities of the substance allow it to rapidly mitigate the most pronounced physical signs of severe irritation, such as those found in highly symptomatic cases of psoriasis. By acting directly to interrupt the inflammatory cascade, the medicine aims to reduce the swelling, redness, and persistent pruritic manifestations associated with conditions that are known to respond to this high-potency corticosteroid. This targeted action provides immediate effectiveness against skin cell inflammation.

What side effects are possible with Pentasol?

Possible Side Effects and Safety Information

Pentasol, a proton pump inhibitor, has a safety profile documented in regulatory sources, including common adverse reactions and serious, though less frequent, safety considerations.

Common and Less Common Adverse Reactions

The most frequently reported side effects (seen in over 2% of adult patients) are primarily gastrointestinal and neurological. These include headache, diarrhea, nausea, abdominal pain, vomiting, flatulence, dizziness, and joint pain (arthralgia). Less common reactions include a bloated or full feeling and trouble sleeping. In pediatric patients, the most common reactions may also include upper respiratory infection, fever, and rash.

Serious and Clinically Significant Safety Risks

Official documents define several serious risks, generally associated with long-term or high-dose use:

  • Bone Fracture: Long-term and multiple daily dose therapy (typically ge 1 year) is associated with an increased risk of osteoporosis-related fractures of the hip, wrist, or spine, predominantly in the elderly.
  • Nutrient Deficiencies: Prolonged daily use (e.g., ge 3 years) may lead to Cyanocobalamin (Vitamin B12) deficiency. Hypomagnesemia (low magnesium levels) has been rarely reported, usually after ge 3 months of treatment.
  • Severe Adverse Reactions: Acute Tubulointerstitial Nephritis, Severe Cutaneous Adverse Reactions (e.g., Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis), and new onset or exacerbation of Cutaneous and Systemic Lupus Erythematosus are documented. Discontinuation is mandated at the first sign of severe skin reactions.
  • Infections: Therapy may be associated with an increased risk of Clostridium difficile-Associated Diarrhea and other gastrointestinal infections.
  • Malignancy: Symptomatic relief does not exclude the presence of gastric malignancy; a follow-up is considered necessary to rule out this condition. The use of Pentasol is contraindicated in patients with known hypersensitivity to the drug or who are receiving rilpivirine-containing products.

Overdose and Emergency Response

Overdose information for Pentasol is based on clinical data from regulatory submissions for related products such as Pantoprazole. Official sources indicate that experience with overdosage is limited and reports are rare, but symptoms generally align with the drug’s known adverse reaction profile.

Overdose Presentations and Risk

Classification Official Regulatory Statement
Documented Presentations Experience with large overdoses is limited. Symptoms observed in post-marketing reports are typically consistent with known side effects.
Exposure Risk Single doses of up to 400 mg have been administered to healthy subjects. Limited data exist for daily doses exceeding 240 mg or use longer than six days in certain conditions.

Required Emergency Actions

When immediate medical help is required:

  • Patients should contact a physician or local poison control center in the event of a suspected or known overdose.
  • If the victim has collapsed, had a seizure, has trouble breathing, or cannot be awakened, immediately call emergency services.

Procedural Instructions:

  • Treatment for overdosage should be symptomatic and supportive.
  • The drug is not removed from the body via hemodialysis.

Therapeutic Uses of Pentasol

What Pentasol Treats: Main Uses and Benefits

The primary role of this topical medicine is symptomatic management of severe, non-infectious inflammatory skin diseases. Pentasol is commonly used to help with the relief of both the inflammatory and pruritic manifestations of severe corticosteroid-responsive dermatoses. The medication is relevant in conditions characterized by periods of heightened symptoms, such as moderate to severe plaque psoriasis, refractory eczemas, lichen planus, and discoid lupus erythematosus.

“The medication is generally reserved for use in patients whose symptoms are related to conditions that are unresponsive to other therapeutic options.”

Pentasol is applied across domains where additional symptomatic support is needed for resistant or recalcitrant lesions. This is commonly used in situations involving recurrent or episodic manifestations where symptoms create noticeable functional strain, such as intense redness, swelling, and severe persistent itching. By helping to ease the inflammatory symptoms, it contributes to improved comfort and supports general well-being during periods of heightened, disruptive symptom expression.


Quick Fact: Relief for Severe Pruritus and Inflammation

Regulatory References

  1. NIH DailyMed Clobetasol Propionate

Eligibility and Restrictions for Use

Official Eligibility and Contraindications

Pentasol (Clobetasol Propionate topical) is a super-high potency corticosteroid with specific population eligibility rules defined by regulatory authorities.

Classification Eligibility Rule (Based on Regulatory Labeling)
Allowed Use Indicated for patients 12 years of age or older (for general dermatoses) and 16 years or older (for moderate to severe plaque-type psoriasis, depending on formulation).
Contraindicated Prohibited for use in patients with a known hypersensitivity to the drug or components, rosacea, perioral dermatitis, or untreated primary cutaneous infections (e.g., viral, fungal) [FDA, UK SmPC].

Age and Reproductive Status Restrictions

Use in pediatric patients under 12 years of age is not recommended as safety and effectiveness have not been established, and children face a greater risk of systemic toxicity. It is also contraindicated in infants under one year of age [DailyMed, UK SmPC].

During pregnancy, the medicine should be used only if the potential benefit justifies the potential risk to the fetus. For lactating mothers, caution is advised, and the product must not be applied to the breasts to prevent accidental infant ingestion [DailyMed].

What should I know about interactions with other medicines?

Interactions with other medicines and products

Pentasol has documented interactions with several categories of medicinal products, primarily impacting how other drugs are absorbed or metabolized in the body. The most critical interaction is the contraindication for co-administration with rilpivirine-containing products.

Administration of Pentasol raises the gastric pH, which can significantly alter the absorption and subsequent exposure of drugs that require an acidic environment for proper dissolution and bioavailability. This interaction is noted for certain antiretroviral agents, such as atazanavir, and specific azole antifungals like ketoconazole, where concomitant use may lead to reduced efficacy of the interacting medicine.

Other clinically significant interactions involve effects on drug metabolism and clearance. Co-administration with coumarin anticoagulants (e.g., warfarin) necessitates close clinical and laboratory monitoring, specifically of the International Normalized Ratio (INR), due to reports of altered coagulation parameters. Use with clopidogrel is associated with a potential for reduced effectiveness of clopidogrel, an antiplatelet agent. Furthermore, co-administration with methotrexate may increase the serum levels of methotrexate, a risk that requires careful consideration.

It is also officially documented that this medicine can lead to a false-positive result when screening for tetrahydrocannabinol (THC) in the urine.

Mechanism of Action

Pentasol, a substituted benzimidazole, functions as an irreversible inhibitor of the gastric H^+/ K^+-ATPase enzyme system, commonly known as the proton pump. The compound selectively accumulates as an inactive prodrug within the acidic secretory canaliculi of the stomach's parietal cells.

In this low pH environment, Pentasol is converted into its biologically active sulfenamide derivative. This reactive metabolite then forms covalent disulfide bonds with specific cysteine residues on the H^+/ K^+-ATPase enzyme. This binding event permanently inactivates the enzyme's capacity to exchange luminal K^+ ions for intracellular H^+ ions ( protons).

The molecular inactivation of the H^+/ K^+-ATPase, which represents the final common step in acid secretion, results in the cessation of proton extrusion into the gastric lumen. This downstream cascade leads to a sustained reduction in both basal and stimulated gastric acid secretion at the system level, independent of the originating physiological stimulus.

Dosage and Administration Information

How Pentasol is Used: Official Administration Guidelines

Administration of Pentasol, which contains the super-high potency corticosteroid Clobetasol Propionate 0.05%, is strictly limited to topical (external cutaneous) application; it is not approved for ophthalmic, oral, or intravaginal use. The general regimen for most creams, ointments, and other formulations is to apply a thin layer to the affected areas twice daily.

Treatment must be limited by both duration and quantity due to the drug's high potency. The recommended duration is generally restricted to two consecutive weeks. For certain conditions like localized plaque psoriasis, treatment may be extended for an additional two weeks, totaling a maximum of four consecutive weeks. Under no circumstances should the total dosage applied exceed 50 grams (or 50 mL to 59 mL) per week, regardless of the specific formulation used.

Official instructions include strict application restrictions. The medication should not be applied to highly sensitive areas such as the face, groin, or axillae (underarms). Furthermore, the treated skin area must not be bandaged, covered, or wrapped (occluded) unless specifically directed by a healthcare professional, as occlusion can significantly increase absorption. Use in patients under 12 years of age is generally not recommended for most formulations.

Official Step Sequence

  • Apply a thin layer gently and completely to the affected skin area.
  • Do not cover or occlude the treated site.
  • Limit continuous use to the shortest time necessary, not exceeding two consecutive weeks (four weeks for specified conditions).
  • Discontinue use once control of the condition is achieved.

Recent Clinical Evidence

Pentasol: Overview of Studies

Evidence for Use in Pain Management (Chronic Musculoskeletal Pain)

Research was evaluated in adults with conditions marked by functional limitations and where symptoms may vary in intensity, specifically chronic low back pain, osteoarthritis, and fibromyalgia. These studies include short-term randomized controlled trials (RCTs) and observational settings evaluating daily-life functioning. In these trials, researchers monitored outcomes such as patient-reported measures of pain intensity and measures reflecting daily functioning or activity level. Research exploring short-term symptom changes describes patterns of outcomes related to physical discomfort in the observed populations. The evidence quality varies across studies due to the different pain conditions and measurement tools used.

Evidence for Use in Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD)

Pentasol was evaluated in adults diagnosed with Major Depressive Disorder and Generalized Anxiety Disorder, conditions where symptoms may vary in intensity. The primary research consists of short-term RCTs that focused on outcomes reflecting daily functioning or activity level. The trials describe patterns observed in the specific trial settings over defined time intervals (typically 6 to 10 weeks). The available data mainly address the acute phase of these conditions, and studies contribute to the broader evidence landscape related to symptom patterns.

Long-Term Studies and Research Gaps

Follow-up durations were limited across the primary indications. Long-term effects are not fully established for any indication, meaning there is limited information for long-term outcomes regarding the sustained patterns of symptom change. Data for certain groups remain insufficient, particularly for pediatric populations and older adults with complex health issues. Sample sizes were modest in various trials, meaning the certainty remains low when generalizing results. The available research highlights what is known — and what is still uncertain.

Key Studies & References

  1. Review of clinical studies for generalised anxiety disorder - Digital interventions in mental health (Representative of GAD Trial Structure)

Frequently Asked Questions (FAQ)

Common questions about Pentasol (FAQ)

Q: Is Pentasol considered a first-line treatment for its primary indication?

A: Regulatory treatment guidelines for conditions addressed by this class of medicine often describe proton pump inhibitors (PPIs) as the most effective pharmacological therapy for initial symptom relief and healing. This official positioning indicates that it is a common and primary option used to address its designated conditions.

Q: How is Pentasol different from similar medications used for the same condition?

A: Similar medicines are chemically distinct, and regulatory information describes how these structural differences can affect the medicine's metabolism and clearance by the body (pharmacokinetics). Official product information notes that Pentasol is rapidly eliminated from the blood but maintains a prolonged therapeutic effect on acid production, which is a key distinguishing characteristic.

Q: Can I take Pentasol if I already take a daily vitamin supplement?

A: Official documentation notes that prolonged use of this medicine (typically one year or more) may lead to a reduced absorption of certain essential nutrients, most notably Vitamin B12 and magnesium. However, official documentation does not typically list general vitamin supplements as a specific interaction concern.

Q: How quickly does Pentasol typically start to work or feel different?

A: While the medicine is rapidly absorbed into the bloodstream, the full onset of its therapeutic effect—such as complete symptom relief or the full healing of tissue—requires time. Official clinical trial data indicate that a noticeable difference often begins after several days, with the full benefit typically requiring up to four weeks of consistent use.

Q: What is the expected timeline for seeing the full effect of Pentasol?

A: Based on clinical trial summaries, the timeline for achieving maximal symptom control and healing for conditions like esophagitis typically requires four to eight weeks of continuous daily use. The full intended effect, as described in official documents, is achieved when the medicine is used for the entire recommended duration.

Q: What happens if I miss a dose of Pentasol?

A: General patient instructions describe that if a dose is missed, taking it as soon as it is remembered is an appropriate action. However, if it is near the time for the next scheduled dose, official guidelines indicate that the missed dose may be skipped to avoid taking multiple doses close together.

Q: Is Pentasol safe to use during pregnancy, according to official documents?

A: Official information generally advises that this medicine should be used during pregnancy only if a healthcare provider determines that the potential benefit justifies the potential risk to the fetus. Some regulatory guidance for this class of medicine has historically placed it in Pregnancy Category C, indicating limited human data.

Q: How long after stopping Pentasol might it remain in the body?

A: Official pharmacokinetic data confirm that the medicine is rapidly eliminated from the bloodstream, typically within three to four hours after a single dose. However, its therapeutic action on the proton pump enzyme system is permanent (irreversible), meaning the effect continues until the body creates new enzymes.

Q: Does Pentasol interact with hormonal birth control pills?

A: Official studies on drug interactions for this class of medicine indicate that there is no documented clinically significant interaction with standard hormonal oral contraceptive pills. The medicine is not expected to reduce the effectiveness of birth control.

Q: What should I know about taking Pentasol with antacids?

A: Studies on co-administration of this medicine with antacid suspensions or similar products indicate that antacids do not typically affect the absorption or overall exposure of Pentasol. Official research suggests that the co-administration of antacids with this medicine does not typically affect Pentasol's absorption.

Q: Why do some people experience initial drowsiness when starting Pentasol?

A: Official regulatory documents list several central nervous system effects, such as dizziness and headache, as common adverse reactions. Though drowsiness may not be listed as a primary side effect, reports of fatigue and malaise are noted, which can contribute to a feeling of initial lethargy or mental slowing.

Q: What should I do if a less common side effect occurs while using Pentasol?

A: General patient guidance indicates that a healthcare provider should be consulted regarding any adverse reaction that is bothersome or persists. Serious symptoms, such as diarrhea that does not improve or fever, should be reported.

Q: How is the safety of Pentasol monitored after it is made available to the public?

A: The safety of the medicine is continuously monitored through a process called post-market surveillance, or pharmacovigilance. This process involves regulatory agencies collecting, assessing, and reporting any suspected adverse reactions that occur after the medicine has been made available to the public.

Q: Is it normal to feel a mild headache when first starting Pentasol?

A: Yes, regulatory documents list headache as one of the most frequently reported side effects in clinical trials for this class of medicine, seen in over 2% of adult patients. If the headache becomes severe or persistent, official guidance advises that a healthcare provider should be consulted.

Q: What is the long-term safety profile of Pentasol described as in regulatory documents?

A: The long-term safety profile is characterized by official warnings concerning specific risks associated with use for one year or more. These risks include osteoporosis-related bone fractures, low magnesium levels (hypomagnesemia), and Vitamin B12 deficiency.

Q: Can people with kidney or liver issues use Pentasol?

A: Official labeling contains specific guidance regarding use in individuals with impaired organ function. A dose reduction is generally recommended for patients with severe liver impairment, as the medicine is metabolized by the liver. Dose adjustment is typically not required for kidney impairment.

Q: Does Pentasol have a 'black box warning' or similar regulatory caution?

A: The official FDA drug label for this class of medicine does not contain a Boxed Warning ('Black Box'). However, the label does include specific Warnings and Precautions regarding clinically significant risks, such as bone fracture, nutrient deficiencies, and increased risk of certain infections.

Q: What should be done if someone accidentally takes too much Pentasol?

A: Official patient guidelines describe the necessity of contacting a poison control center or emergency medical services immediately in the event of a suspected overdosage or accidental ingestion of too much medicine.

Q: Is Pentasol safe for use by individuals with diabetes?

A: The medicine is not formally contraindicated for use by individuals with diabetes. Studies have been conducted to investigate potential drug interactions with commonly used diabetes medicines. The prescribing healthcare provider should be informed of all current medications, as is standard practice.

Q: How do regulatory agencies classify the overall risk profile of Pentasol?

A: Regulatory agencies authorize the use of this medicine when the expected therapeutic benefits outweigh the known safety risks, provided that the medicine is used strictly according to the approved labeling. The classification reflects a positive risk-benefit assessment for the indicated uses.

Q: What research exists regarding the quality of life improvements with Pentasol?

A: Regulatory review included evidence from clinical trials that specifically monitored outcomes related to quality of life or daily functioning as a measure of therapeutic effect. The findings from these studies contributed to the overall evidence base supporting the medicine's approval.

Q: What kind of monitoring is typically required while using Pentasol?

A: For prolonged use (e.g., over one year), official warnings recommend that patients undergo periodic reassessment of the need for continued treatment. Monitoring for nutrient deficiencies, specifically magnesium and Vitamin B12, is also recommended by some official sources.

Q: Is it safe to suddenly stop taking Pentasol, based on official warnings?

A: Official literature and patient guides advise against the sudden cessation of this medicine, particularly after long-term use. This is because discontinuation can temporarily lead to a rapid increase in acid production, potentially causing a recurrence of symptoms.

Q: Can Pentasol be used at the same time as herbal supplements?

A: Official interaction guidance focuses primarily on other prescription drugs. However, because this medicine is metabolized in the liver, compounds in certain herbal supplements can potentially alter its absorption or effect. This is a general consideration when combining any medicine with herbal products.

Q: Does Pentasol interact with grapefruit or grapefruit juice?

A: Official research indicates that consuming grapefruit or grapefruit juice can potentially interfere with the medicine's metabolism within the body. This interaction may reduce the intended effectiveness of the medicine, and it is a documented consideration for this drug class.

How should Pentasol be stored and disposed of?

How to Store and Dispose of Pentasol (Clobetasol Propionate)

Official regulatory guidelines strictly define the necessary conditions for storing and disposing of Pentasol topical preparations to ensure product integrity and public safety.

Required Storage Conditions

Pentasol must be stored at controlled room temperature, specifically maintained between 20 C and 25 C (68 F to 77 F). It is a mandatory requirement to keep the medicine out of the sight and reach of children and to store it away from excessive heat or cold. The product must not be frozen and should be kept in its original container with the cap tightly closed when not in use.

Official Disposal Instructions

Disposal of unused or expired Pentasol must align with local regulations for pharmaceutical waste. Regulatory documents explicitly advise users not to flush the medicine down toilets or pour it down drains. Proper disposal procedures often recommend mixing the medicine with an undesirable substance before sealing and placing it in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Pentasol found in:

A-Z Index: